Lee et al. (2019). PRISM: methylation pattern-based, reference-free inference of subclonal makeup. Bioinformatics.
Stieglitz et al. (2017). Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nature Communications.
Eisfeld et al. (2017). The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia.
Glass et al. (2017). Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer discovery.
Döhner et al. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood.
Ng et al. (2016). A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature.
Guryanova et al. (2016). DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine.
Papaemmanuil et al. (2016). Genomic Classification and Prognosis in Acute Myeloid Leukemia. The New England journal of medicine.
Grimwade et al. (2016). Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood.
Garrett-Bakelman et al. (2015). Enhanced reduced representation bisulfite sequencing for assessment of DNA methylation at base pair resolution. Journal of visualized experiments : JoVE.
Rampal et al. (2014). DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell reports.
Wertheim et al. (2014). Validation of DNA Methylation to Predict Outcome in Acute Myeloid Leukemia by Use of xMELP. Clinical Chemistry.
Li et al. (2014). Dynamic evolution of clonal epialleles revealed by methclone. Genome Biol.
Lugthart et al. (2011). Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood.
Figueroa (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell.
Cripe et al. (2010). Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood.
Figueroa et al. (2010). DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer cell.
Rao et al. (2009). Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
de Jonge et al. (2009). AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood.
Smith et al. (2009). Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation. Journal of Clinical Oncology.
Wilson et al. (2006). Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood.
Valk et al. (2004). Prognostically useful gene-expression profiles in acute myeloid leukemia. The New England journal of medicine.